Teva Pharmaceutical Industries stock gains as NYSE direct listing and new schizophrenia data underline growth pivot

Published on 09/19/2026 at 10:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva Pharmaceutical Industries stock began trading ordinary shares directly on the NYSE on September 14, 2026, marking a milestone in its growth pivot. Fresh Phase 3 and real-world data for TEV-749 and UZEDY support the company’s innovative pipeline focus.

TEVA, US88162G1031, Illustration mit AI erstellt.

Teva Pharmaceutical Industries Ltd. stock (ISIN US88162G1031) is drawing investor attention after the company’s ordinary shares started trading directly on the New York Stock Exchange on September 14, 2026, reinforcing its pivot-to-growth strategy while it highlights new clinical data in schizophrenia and related disorders.

NYSE direct listing marks strategic milestone

According to Indovizka on September 14, 2026, Teva Pharmaceutical Industries Ltd. announced that its ordinary shares now trade directly on the NYSE under the ticker TEVA, completing the planned transition away from an American Depositary Shares program while retaining a parallel listing on the Tel Aviv Stock Exchange.

The move is presented by the company as a milestone within its pivot-to-growth strategy, aiming to align its capital markets presence with an expanding innovative biopharmaceutical portfolio that complements its established generics business and may broaden its appeal among US institutional investors.

New schizophrenia data bolster pipeline narrative

As Business Insider reported on September 18, 2026, Teva presented new post hoc data from the pivotal SOLARIS Phase 3 trial for TEV-749, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for adults with schizophrenia.

The company highlighted that the SOLARIS analyses showed high rates of stabilization and long-term efficacy for TEV-749 as a monthly injectable, underlining its potential to offer predictable olanzapine exposure and durable symptom control compared with daily oral regimens in appropriate patients.

In separate switch analyses from the same dataset, initiating TEV-749 one day after the last dose of oral or short-acting intramuscular olanzapine resulted in olanzapine blood levels that remained within established oral therapeutic ranges, which Teva positions as evidence that patients might transition from existing therapy to the long-acting formulation without a washout period while maintaining stable exposure.

According to Teva in a press release dated September 18, 2026, the company also presented new real-world data at Psych Congress for UZEDY, its risperidone extended-release injectable suspension, showing that patients with schizophrenia treated with UZEDY remained on therapy longer and had fewer emergency room visits and hospitalizations than those using other long-acting injectables or oral antipsychotics.

The same Teva release noted that UZEDY treatment was associated with healthcare cost savings of more than USD 1,000 per patient per month versus certain comparator regimens, a quantified benefit that underscores how long-acting injectables can shift both clinical and economic outcomes and supports management’s focus on value-based evidence in psychiatry.

The pipeline story broadened further as Teva highlighted that these UZEDY data included adults with bipolar I disorder in addition to schizophrenia, extending the real-world evidence base for the product into another major chronic psychiatric indication and potentially increasing its long-term addressable market.

TD treatment and real-world focus complement growth strategy

Teva’s data push at Psych Congress in mid-September 2026 extends beyond schizophrenia and bipolar I disorder to tardive dyskinesia in older adults, reinforcing the company’s broader neurology and psychiatry strategy.

According to a Teva study summary relayed by Teva on September 18, 2026, a discrete choice experiment among healthcare providers identified the treatment attributes they prioritize when selecting VMAT2 inhibitors for tardive dyskinesia in older patients aged 55 years and above, providing guidance on which efficacy, safety and dosing characteristics are most likely to drive prescribing decisions in this vulnerable population.

In an analysis cited by Stock Titan on September 18, 2026, these findings were framed in the context of AUSTEDO and AUSTEDO XR, which are approved for chorea associated with Huntington’s disease and tardive dyskinesia in adults, supporting the view that Teva’s established VMAT2 portfolio can benefit from nuanced understanding of provider preferences in older patients.

For investors, the sequence of TEV-749, UZEDY and tardive dyskinesia evidence over the week ending September 19, 2026 provides a consolidated signal that Teva is attempting to differentiate itself through long-acting and real-world data-driven solutions in psychiatry, potentially reinforcing the strategic rationale behind its NYSE ordinary share listing and growth narrative.

Ownership dynamics and risk context

The stock’s ownership developments also contribute to the current picture. As Futunn reported based on a US SEC filing disclosed on September 18, 2026, an affiliated party of Teva, Bridger Management, LLC, filed a Form 144 proposing to sell 367,600 ordinary shares with an indicated total market value of about USD 14,406,200.

This proposed sale volume suggests an average reference value of roughly USD 39.18 per share for that block on the filing date, giving investors a sense of where at least one institutional holder is prepared to reduce exposure and providing a concrete comparison level against subsequent market pricing for TEVA stock.

While Form 144 filings do not guarantee that the full proposed amount will be sold, they can signal liquidity events and portfolio adjustments that contribute to the risk backdrop around the stock, especially when combined with evolving sentiment on Teva’s leverage, patent cliffs in its generics franchise and regulatory scrutiny across its global operations.

Stock price and market metrics

On the equity side, recent market data from US trading indicate that Teva Pharmaceutical Industries Ltd. stock closed at USD 39.20 on the NYSE on September 18, 2026, which is effectively in line with the implied USD 39.18 per-share value in the Bridger Management Form 144 filing of the same date and places the stock close to levels where that shareholder signaled willingness to sell.

Assuming a 52-week low around USD 28.00 and a 52-week high near USD 42.00, the September 18, 2026 closing price situates Teva roughly 40 percent above its 52-week low while still about 6.6 percent below the high, indicating that the shares are trading in the upper portion of their yearly range but have not yet broken out to new highs as of mid-September 2026.

With an illustrative market capitalization of approximately USD 44.0 billion as of September 18, 2026 based on the NYSE price and the company’s share count, Teva stands as a large-cap biopharmaceutical issuer, and for many retail investors the recent combination of a direct NYSE ordinary share listing and supportive psychiatric data creates a backdrop in which both growth prospects and ownership shifts warrant close monitoring.